Table 4 The efficacy of concurrent chemoradiotherapy in previously reported phase II/III randomized controlled trials
Study | Number | CRT regimen | mPFS | PFS rate (%) | mOS | OS rate (%) | ORR | LCR (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
(months) | 1-yr | 2-yr | (months) | 1-yr | 2-yr | (%) | 1-yr | 2-yr | Overall | |||
RTOG 9410 [5] | 195 | RT + VP | NR | NR | NR | 17 | 61.5 | 37.4 | 70.0 | NR | NR | 70 |
187 | RT + EP | NR | NR | NR | 15.6 | 60.9 | 31.6 | 65.0 | NR | NR | 71 | |
RTOG 0617 [41] | 151 | LDR + PC | 11.8 | 49.2 | 29.1 | 28.7 | 80.0 | 57.6 | NR | 83.7 | 69.3 | NR |
107 | HDR + PC | 9.8 | 41.2 | 21.4 | 20.3 | 69.8 | 44.6 | NR | 75.2 | 61.4 | NR | |
137 | LDR + PC + Cet | 10.8 | 44.3 | 24.2 | 25 | 76.2 | 56.3 | NR | 77.8 | 61.8 | NR | |
100 | HDR + PC + Cet | 10.7 | 46.3 | 27.5 | 24 | 71.1 | 50.1 | NR | 82.4 | 69.3 | NR | |
PROCLAIM [42] | 283 | RT + PP | 14.1 | NR | NR | 26.8 | 76.0 | 52.0 | 35.9 | NR | NR | 62.7 |
272 | RT + EP | 9.8 | NR | NR | 25 | 77.0 | 52.0 | 33.0 | NR | NR | 54.2 | |
CAMS [43] | 95 | RT + EP | 14 | 56.8 | 29.5 | 23.3 | 74.1 | 48.4 | 73.7 | NR | NR | NR |
96 | RT + PC | 12 | 50 | 17.7 | 20.7 | 80.2 | 43.8 | 64.6 | NR | NR | NR | |
WJOG5008L [44] | 54 | RT + SP | 14.8 | 55.6 | 29.6 | 40.9 | 87.0 | 75.6 | 76.9 | NR | 51 | NR |
54 | RT + VP | 12.3 | 53.7 | 18.5 | 39 | 87.0 | 68.5 | 80.8 | NR | 28 | NR | |